Literature DB >> 31776463

De novo variation in bipolar disorder.

Fernando S Goes1, Mehdi Pirooznia2, Martin Tehan2, Peter P Zandi2, John McGrath2, Paula Wolyniec2, Gerald Nestadt2, Ann E Pulver2.   

Abstract

Bipolar disorder (BD) is a common, highly heritable disorder that affects 1-2% of the world's population. To date, most genetic studies of BD have focused on common gene variation, and while robustly associated loci have been identified, a substantial proportion of the heritability remains missing and could be partially attributable to rare variation. In this study, we apply a de novo paradigm in BD to identify newly arisen variants that have yet to undergo natural selection and may represent highly pathogenic variants. We performed whole genome sequencing of 97 trios of Ashkenazi Jewish descent, selecting "simplex" families with no family history of BD and an early age of onset. We found a total of 6882 de novo variants (an average of 70.9 ± 12.9 S.D. variants per trio), including 107 variants within protein-coding genes. We combined our exonic variations with the results of 79 previously published BD trios, identifying 20 loss-of-function (LoF) and 77 missense damaging de novo variants in BD. These variants showed significant enrichment for constrained genes and for genes located to the postsynaptic density (PSD) (all Bonferroni corrected p < 0.05). Pathway analyses showed enrichment in several pathways, including "Phosphoinositides (PI) and their downstream targets" (Bonferroni p = 4.2 × 10-6), a pathway prominently featured in lithium's hypothesized mechanism of action. In addition, while we found overall evidence for transmission of common variant polygenic risk of BD in our full sample (pTDT p = 2.21 × 10-4), specific trios with LoF variants showed no evidence of polygenic transmission. In sum, our findings support the de novo paradigm as a contributor to the genetic architecture of BD and provide evidence that constrained genes, as well as genes within the PSD and PI pathway harbor rare variation associated with BD.
© 2019. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2019        PMID: 31776463     DOI: 10.1038/s41380-019-0611-1

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  40 in total

1.  Estrogen receptor content and hormone-responsive growth of mouse mammary tumors.

Authors:  M Sluyser; R Van Nie
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

2.  [The aims and objectives of the Tuberculosis Research Center of the Tuberculosis Institute cooperating with WHO and UNICEF].

Authors:  J Leowski
Journal:  Gruzlica       Date:  1972-11

3.  Effect of Ovulen and Depo-Provera on primary and secondary immune response in mice and rats.

Authors:  U M Joshi; K N Rangnekar; S S Rao
Journal:  J Reprod Fertil       Date:  1971-11

4.  In vitro activity of bursal lymphocytes from two lines of chickens.

Authors:  P G Kulkarni; L J Dreesen; J Love; B Glick
Journal:  Exp Cell Res       Date:  1971-05       Impact factor: 3.905

5.  Monoclonal antibodies suppress replication of herpes simplex virus type 1 in trigeminal ganglia.

Authors:  J E Oakes; R N Lausch
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

6.  Priming pheromones from oestrous cows increase synchronization of oestrus in dairy heifers after PGF-2 alpha injection.

Authors:  M K Izard; J G Vandenbergh
Journal:  J Reprod Fertil       Date:  1982-09

7.  Preparation of small temporal bones for high-resolution light microscopy.

Authors:  R A Chole; G L Charpied
Journal:  Arch Otolaryngol       Date:  1981-10

8.  The effect of a low protein diet on the response of rat colonic and hepatic ornithine decarboxylase activity to sodium deoxycholate and thioacetamide treatment.

Authors:  J M Siegler; M N Kazarinoff
Journal:  J Nutr       Date:  1984-03       Impact factor: 4.798

9.  [Mechanism of morphine-induced suppression of central nervous system blood flow].

Authors:  S Dohi; N Matsumiya; T Abe
Journal:  No To Shinkei       Date:  1983-11

10.  [Effect of phytoecdysteroids and steranobols on the activity and stability of membrane-bound enzymes of liver mitochondria in experimental hepatitis].

Authors:  M A Tashmukhamedova; K T Almatov; Z A Khushbaktova; V N Syrov
Journal:  Vopr Med Khim       Date:  1986 Jan-Feb
View more
  5 in total

1.  dbBIP: a comprehensive bipolar disorder database for genetic research.

Authors:  Xiaoyan Li; Shunshuai Ma; Wenhui Yan; Yong Wu; Hui Kong; Mingshan Zhang; Xiongjian Luo; Junfeng Xia
Journal:  Database (Oxford)       Date:  2022-07-02       Impact factor: 4.462

2.  Amygdala and anterior cingulate transcriptomes from individuals with bipolar disorder reveal downregulated neuroimmune and synaptic pathways.

Authors:  Peter P Zandi; Andrew E Jaffe; Fernando S Goes; Emily E Burke; Leonardo Collado-Torres; Louise Huuki-Myers; Arta Seyedian; Yian Lin; Fayaz Seifuddin; Mehdi Pirooznia; Christopher A Ross; Joel E Kleinman; Daniel R Weinberger; Thomas M Hyde
Journal:  Nat Neurosci       Date:  2022-03-07       Impact factor: 28.771

3.  Systematic analysis of exonic germline and postzygotic de novo mutations in bipolar disorder.

Authors:  Masaki Nishioka; An-A Kazuno; Takumi Nakamura; Naomi Sakai; Takashi Hayama; Kumiko Fujii; Koji Matsuo; Atsuko Komori; Mizuho Ishiwata; Yoshinori Watanabe; Takashi Oka; Nana Matoba; Muneko Kataoka; Ahmed N Alkanaq; Kohei Hamanaka; Takashi Tsuboi; Toru Sengoku; Kazuhiro Ogata; Nakao Iwata; Masashi Ikeda; Naomichi Matsumoto; Tadafumi Kato; Atsushi Takata
Journal:  Nat Commun       Date:  2021-06-18       Impact factor: 14.919

Review 4.  Genetic contributions to bipolar disorder: current status and future directions.

Authors:  Kevin S O'Connell; Brandon J Coombes
Journal:  Psychol Med       Date:  2021-04-21       Impact factor: 7.723

Review 5.  Genomic and neuroimaging approaches to bipolar disorder.

Authors:  Mojtaba Oraki Kohshour; Sergi Papiol; Christopher R K Ching; Thomas G Schulze
Journal:  BJPsych Open       Date:  2022-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.